Fluticasone Chemical Structure (Advairhfa Spl Graphic 01)
Advair Hfa Aerosol, Metered
Product Images NDC 50090-3672
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Advair Hfa (NDC 50090-3672). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Salmeterol Chemical Structure (Advairhfa Spl Graphic 02)
Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects Previously Treated With Either Beta2 Agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 03)
Figure 2. Mean Percent Change From Baseline In Morning Peak Expiratory Flow In Subjects Previously Treated With Inhaled Corticosteroids (trial 4) (Advairhfa Spl Graphic 04)
Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 05)
This text appears to be describing a comparison of changes in Forced Expiratory Volume in one second (FEV1) among individuals using two different inhalers over a certain period of time. The study includes participants using Advair HFA inhaler and Fluticasone Propionate inhalation aerosol with Salmeterol inhalation aerosol. The treatments were administered twice daily with specified dosages. The text also mentions Day 1 and Baseline as reference points in the study.*
Figure 4. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 06)
This is a report comparing the efficacy of ADVAIR HFA, Fluticasone propionate inhalation aerosol, Salmeterol inhalation aerosol, and Placebo in terms of % Change in Forced Expiratory Volume (FEV) over 12 weeks. The study included different number of participants for each treatment group. The data is presented in a graphical form showing the change in FEV over time.*
Figure A (Advairhfa Spl Graphic 07)
This text describes a metal canister with a purple plastic actuator, a purple mouthpiece, and a light purple cap. It may be a container used for storing or dispensing a product.*
Figure B (Advairhfa Spl Graphic 08)
Figure C (Advairhfa Spl Graphic 09)
Figure D (Advairhfa Spl Graphic 10)
Figure E (Advairhfa Spl Graphic 11)
This text provides information about the "Mouthpiece-Down" position of a purple mouthpiece. The description seems to be related to a musical instrument or possibly a sports equipment.*
Figure F (Advairhfa Spl Graphic 12)
"Breathe out as much air as you can"*
Figure G (Advairhfa Spl Graphic 13)
Figure H (Advairhfa Spl Graphic 14)
Figure I (Advairhfa Spl Graphic 15)
Figure J (Advairhfa Spl Graphic 16)
Label Image (Lbl500903672)
This is a description of an Advair HFA inhalation aerosol medication. Each actuation delivers 115 mcg of fluticasone propionate and 30.45 mcg of salmeterol xinafoate, equivalent to 70.21 mcg of salmeterol base from the mouthpiece. The inhaler should be stored at 68 to 77 degrees F with the mouthpiece down. It has 120 metered actuations and is distributed by A-S Medication Solutions from Libertyville, IL.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
